Published in Maturitas on November 19, 2010
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer. Ann Oncol (2011) 1.11
Current treatment strategies for castration-resistant prostate cancer. Korean J Urol (2011) 0.93
The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol (2011) 0.93
Progress of molecular targeted therapies for prostate cancers. Biochim Biophys Acta (2011) 0.89
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (2010) 19.74
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol (1994) 3.19
CYP17 polymorphisms and prostate cancer outcomes. Prostate (2010) 0.95
Conversion of pregnenolone to DHEA by human 17alpha-hydroxylase/17, 20-lyase (P450c17). Evidence that DHEA is produced from the released intermediate, 17alpha-hydroxypregnenolone. Eur J Biochem (2000) 0.88
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88
Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol (2013) 2.84
Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol (2013) 2.59
The Melbourne Consensus Statement on the early detection of prostate cancer. BJU Int (2014) 2.32
Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park) (2010) 2.22
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol (2009) 2.16
The Research on Adverse Drug Events and Reports (RADAR) project. JAMA (2005) 2.08
Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone. Urology (2013) 2.04
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer (2014) 1.76
Racial variation in CAG repeat lengths within the androgen receptor gene among prostate cancer patients of lower socioeconomic status. J Clin Oncol (2002) 1.71
A tale of two citizens: a State Attorney General and a hematologist facilitate translation of research into US Food and Drug Administration actions--a SONAR report. J Oncol Pract (2012) 1.63
Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy. Oncotarget (2014) 1.51
Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project. J Clin Oncol (2003) 1.50
Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect. Ann Intern Med (2002) 1.45
Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future Prospects. Oncology (Williston Park) (2015) 1.44
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol (2008) 1.43
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A (2012) 1.34
A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol (2006) 1.33
Abiraterone in Metastatic Prostate Cancer. N Engl J Med (2017) 1.31
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst (2013) 1.27
Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res (2009) 1.27
Interleukin-17 promotes formation and growth of prostate adenocarcinoma in mouse models. Cancer Res (2012) 1.26
Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int J Radiat Oncol Biol Phys (2013) 1.25
Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes. Stem Cells (2014) 1.20
STAT3: a target to enhance antitumor immune response. Curr Top Microbiol Immunol (2011) 1.18
Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells. Clin Cancer Res (2012) 1.17
Intensity-modulated radiation therapy for prostate cancer. N Engl J Med (2014) 1.15
Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas (2010) 1.11
Berberine suppresses androgen receptor signaling in prostate cancer. Mol Cancer Ther (2011) 1.11
Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol (2008) 1.08
Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes. Prostate (2008) 1.06
Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. Arch Ital Urol Androl (2016) 1.06
Overcoming chemotherapy resistance in prostate cancer. Clin Cancer Res (2011) 1.06
A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost (2012) 1.05
Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer. BJU Int (2011) 1.03
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol (2013) 0.99
Association between pharmaceutical support and basic science research on erythropoiesis-stimulating agents. Arch Intern Med (2010) 0.99
Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer (2005) 0.99
Overview of samarium sm 153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol (2004) 0.97
Radium-223 in prostate cancer. N Engl J Med (2013) 0.97
Suramin's development: what did we learn? Invest New Drugs (2002) 0.97
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res (2009) 0.96
Critical appraisal of cabazitaxel in the management of advanced prostate cancer. Clin Interv Aging (2010) 0.96
Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol (2008) 0.96
Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer. Int J Cancer (2013) 0.95
20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor. Int J Cancer (2012) 0.95
Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR). J Gen Intern Med (2012) 0.94
Clinicians versus nomogram: predicting future technetium-99m bone scan positivity in patients with rising prostate-specific antigen after radical prostatectomy for prostate cancer. Urology (2013) 0.94
A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol (2009) 0.93
Management of non-small-cell lung cancer in the older adult. Maturitas (2011) 0.91
Saposin C promotes survival and prevents apoptosis via PI3K/Akt-dependent pathway in prostate cancer cells. Mol Cancer (2004) 0.91
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer. J Urol (2008) 0.90
The emotional burden of low-risk prostate cancer: proposal for a change in nomenclature. Clin Genitourin Cancer (2006) 0.90
Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone. Clin Genitourin Cancer (2008) 0.89
Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs. J Clin Oncol (2005) 0.87
Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. Clin Prostate Cancer (2004) 0.87
Cognitive changes associated with endocrine therapy for breast cancer. Maturitas (2010) 0.87
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl (2011) 0.87
Management of docetaxel failures in metastatic castrate-resistant prostate cancer. Urol Clin North Am (2012) 0.87
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action. Urology (2004) 0.86
Safety considerations for use of bone-targeted agents in patients with cancer. Semin Oncol (2010) 0.86
Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology (2002) 0.86
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer. World J Urol (2004) 0.85
The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel. Clin Genitourin Cancer (2006) 0.85
Enforcement actions involving Medicaid fraud and abuse, 1996-2009. Arch Intern Med (2011) 0.85
Increased uptake of 18F-fluorodeoxyglucose due to Mycobacterium avium complex in a solitary pulmonary nodule. J La State Med Soc (2008) 0.85
Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells. Asian J Androl (2005) 0.85
Characterization of germline copy number variation in high-risk African American families with prostate cancer. Prostate (2012) 0.84
Prosaptide TX14A stimulates growth, migration, and invasion and activates the Raf-MEK-ERK-RSK-Elk-1 signaling pathway in prostate cancer cells. Prostate (2004) 0.84
Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin Drug Metab Toxicol (2015) 0.84
Androgen-deprivation therapy versus radical prostatectomy as monotherapy among clinically localized prostate cancer patients. Onco Targets Ther (2013) 0.84
Enzalutamide for the treatment of prostate cancer. Expert Opin Pharmacother (2013) 0.82
Chemotherapy in prostate cancer: an update. Clin Genitourin Cancer (2007) 0.81
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int (2008) 0.81
Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int (2005) 0.81
Radiation-based approaches for therapy and palliation of advanced prostate cancer. Curr Opin Urol (2012) 0.80
Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer". Arch Intern Med (2010) 0.80
Does urological cancer mortality increase with low population density of physicians? J Urol (2011) 0.79
Prostate cancer and bone: a unique relationship with multiple opportunities for targeted therapy. Clin Prostate Cancer (2004) 0.79
Underutilization of partial nephrectomy for stage T1 renal cell carcinoma in the United States, trends from 2000 to 2008. A long way to go. Clin Genitourin Cancer (2012) 0.79
Pharmaceutical fraud and abuse in the United States, 1996-2010. Arch Intern Med (2011) 0.79
Radium-223 in metastatic castration resistant prostate cancer. Asian J Androl (2014) 0.79
Society of Urologic Oncology position statement: redefining the management of hormone-refractory prostate carcinoma. Cancer (2005) 0.79
Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape. Nat Rev Clin Oncol (2010) 0.79
Recent advances in the therapy of castration-resistant prostate cancer: the price of progress. Maturitas (2011) 0.79
Androgen deprivation--continuous, intermittent, or none at all? N Engl J Med (2012) 0.79
The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer. Clin Adv Hematol Oncol (2011) 0.78
Radiation for bone metastases. Curr Opin Support Palliat Care (2011) 0.78
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules. Expert Opin Biol Ther (2010) 0.77
Suggestive evidence of linkage identified at chromosomes 12q24 and 2p16 in African American prostate cancer families from Louisiana. Prostate (2011) 0.77
Relationships between reverse transcriptase-polymerase chain reaction for prostate specific antigen, survival, and various prognostic laboratory factors in patients with hormone refractory prostate cancer. Urol Oncol (2005) 0.77